Brimapitide clinical trials
Also written XG-102.
How each study uses brimapitide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Xigen SA (3) · Auris Medical AG (2) · Auris Medical, Inc. (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses brimapitide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- AM-111 in the Treatment of Acute Inner Ear Hearing LossCompletedPhase 3Auris Medical AGNCT02561091Written as AM-111 0.4 mg/ml
- Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss TreatmentTerminatedPhase 3Auris Medical, Inc.NCT02809118Written as AM-111 0.4 mg/ml
- Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular InflammationCompletedPhase 3Xigen SANCT02235272Written as XG-102
- Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and PainCompletedPhase 3Xigen SANCT02508337Written as XG-102
- Efficacy of AM-111 in Patients With Acute Sensorineural Hearing LossCompletedPhase 2Auris Medical AGNCT00802425Written as AM-111
- Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy VolunteersCompletedPhase 1Xigen SANCT01570205Written as XG-102
Codes
What other systems call brimapitide · ClinicalTrials.gg INT004565
- UNII (FDA) 2K30142185BRIMAPITIDEConfirmed FDA, Wikidata
- Wikidata Q27254842brimapitideConfirmed FDA, Wikidata
- NCI Thesaurus C166576BrimapitideOne source FDA
- DrugBank DB15231One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2K30142185 | BRIMAPITIDE | Confirmed FDA, Wikidata |
| Wikidata | Q27254842 | brimapitide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166576 | Brimapitide | One source FDA |
| DrugBank | DB15231 | — | One source Wikidata |
Also registered as brimapitide, c-terminal acid (UNII FU288768DP).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.